Acrivon Therapeutics (ACRV) logo

Acrivon Therapeutics (ACRV) stock

Oncology medicines , market cap $60.1M

After-hours Fri
$1.16
+0.87%

Close $1.15 -17.86%

Why is ACRV down?

Down 49% in a year while the S&P 500 rose 7%.

  • Its $77.8M in cash covers about 5 quarters at the past year's pace; its share count rose 11.2% in a year.
  • Arithmetic on filed figures, not a forecast.

Sources: Price history, Nov 20, 2026; Latest balance sheet, Nov 16, 2026; Quarterly reports, Sep 30, 2026

−3Long-term trend below a falling 200-day average, down over one year, down over two years

Tell me next time ACRV moves

Free account, no card. An optional alert when ACRV moves or its score changes.Pro, $1 for a first month. An optional alert when ACRV moves or its score changes.Pro, 7 days free with a card. An optional alert when ACRV moves or its score changes.

Or see it live, free until Tuesday morning. No account.Or see one stock in full, free. No account.
1 more reason, free with an account →See every reason on ACRV →1 more reason why ACRV lags the market, from its filings, with the other side, the company's words, and the timeline, for Pro members.
Quality Score
-11
Poor
In its industry
#268of 273
Checks firing
1of 14
Trending down
From 52-week high
-67.7%
under its best in a year

Follow ACRV's trial news. Pro members can get an alert when Acrivon Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when ACRV files news on its trialsSee it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextQ4 2026“…inhibitor, in all-comer serous endometrial cancer (EC) treatment arms expected in fourth quarter of 2026”Trial data · SEC filing · Nov 16
Cash$77.8M, about 4 quarters at the last year's spendingOn Sep 30 · the company says “into fourth quarter of 2027”

Key facts on ACRV

Key facts on ACRV
Holding it backMoves 13.6% a day with no profit behind it
Latest filing8-K, Nov 20 Issued a release: "Safety, dose optimization, and early Phase 1/2 clinical results in AP3-predicted tumors for ACR-2316, a first-in-class WEE1/PKMYT1 inhibitor Timothy A. Yap1, Mohamad A. Salkeni2, Neel Gandhi3,…"

ACRV in the news

What's next

Expected to report Thu Mar 18, after the close

After its last 4 reports it closed +2.3% on average, higher 2 of 4 times.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Cash$77.8M, about 4 quarters at the last year's spendingOn Sep 30 · the company says “into fourth quarter of 2027”

ACRV catalysts

Coming up

3 past catalysts since 2026, with sizes and sources, for Pro members.

What's next for ACRV, and how long its cash lasts

Next step the company has named

Q4 2026“Prespecified Phase 2b interim analysis of ACR-368, a selective CHK1/2 inhibitor, in all-comer serous endometrial cancer (EC) treatment arms expected in fourth quarter of 2026”Trial data · SEC filing · Nov 16

What it means: the first look at a trial’s main results, as the company reports them.

Lead program
ACR-368 · Endometrial Adenocarcinoma · Phase 2
Its trial
ACR-368 in Endometrial AdenocarcinomaPhase 2 · Recruiting · 350 people · main data estimated May 30, 2027 · NCT05548296

1 more trial, 34 filings, for Pro members.

Cash runway Sep 30 balance sheet

About 4 quarters

$77.8M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money. The company's estimate is “into fourth quarter of 2027” (8-K, Nov 16).

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3, filed Nov 16, 2026)
  • At-the-market share sales program (S-3, filed Nov 16, 2026)

For Pro members: the amounts, and the share count against a year ago.

Insiders

Chief Accounting Officer Katharine Peterson sold 107 shares on Nov 17. 17 more insider trades this year.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Peter Blume-Jensen’s 29 filings and quotes.

Get an alert when ACRV files news on its trialsA free account. No card.Pro: $1 first month.Pro, 7 days free with a card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

12 more FDA dates and 98 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 144 dates, ranked →See all 144 dates, ranked →Start Pro

How ACRV ranks in Biotech

ACRV is #268 of 273 by Quality Score.

How ACRV ranks in Biotech
RankStockQuality Score
268Acrivon Therapeutics (ACRV) logoACRVAcrivon Therapeutics-11

More in Biotech

When does ACRV report earnings, and what happens after?

Expected to report Thu Mar 18, after the close (in 117 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What ACRV reported on Nov 16, 2026

The quarter

A loss of $0.42 a share, from $0.47.

“The difference was driven by the timing of clinical trial and related costs for ACR-368 and ACR-2316.”

The quarter that ended Sep 30, from the company's press release

The press releaseThe filing on EDGAR

Where the sales came from

ACRV's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

In the company's words

  • “The difference was primarily driven by employee-related expenses, including stock-based compensation expense.”

From its results filing (SEC filing · Nov 16)

The numbers

Market value
$60.1M
today
Free cash flow
-$63.3M
last 12 months

1 more figure, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on ACRV: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

0.0%+7.6%-2.0%
May 13Aug 12Nov 16
ReportedGapReaction5
days
Nov 16, 2026After close-0.7%-2.0%not yet
Aug 12, 2026After close+0.6%+7.6%+39.0%
May 13, 2026After close+2.6%0.0%-8.3%

ACRV closed higher after 2 of its last 4 reports.

All 4 reports, and ACRV's Quality Score going into each

ACRV has 1 of 14 chart checks firing

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on ACRV, and all 14 on every stock.Get in free →See the top 3 →Start Pro

ACRV RSI on Nov 20: 27.3, below its 50-day and 200-day averages

Not scored

RSI 27.3, MACD below signal, below both averages. Not scored.

The deep dive on ACRV

4 more findings on ACRV, each with its source, for Pro members.

ACRV share count over time

11% more shares than a year earlier.

Weighted shares, quarter to Sep 30, 2026, both from one filing

Shares of ACRV outstanding, as filed
Shares
outstanding
As
of
42.9MNov 10, 2026
42.9MAug 7, 2026
42.8MMay 8, 2026
38.7MMar 16, 2026
Offerings, shelves, and splits of ACRV, from its filings
From its
filings
Filed
Registered shares for a later sale (S-3)Nov 16, 2026
Registered shares for a later sale (S-3)Apr 17, 2024
Registered shares for a later sale (S-3)Dec 1, 2023

ACRV insider trades

6 insiders sold $46K across 17 filings in the last 6 months. No open-⁠market buys on record. The newest:

SellPeter Blume-Jensen$2KPresident and CEOat $1.45 on Nov 17, filed Nov 19

All 17 insider filings on ACRV from the last six months, for Pro members.

All ACRV insider trades

ACRV's officers and directors

Officers and directors with a Form 4 in the last 12 months.

7 more officers and directors file at ACRV.

See insider trades by person

Which ETFs hold ACRV?

In ETFs: ACRV is 0.0% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Acrivon Therapeutics

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.

76 employeesWatertown, MAacrivon.com

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on ACRV and every other stock.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would turn ACRV's score around: 8 things
  • 7 more filings explained, a plain line each
  • 6 more things pulling ACRV's score down
BreakawayNov 19Peter Blume-Jensen sold ACRV$2K at $1.45, filed Nov 19

Alerts are optional.

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 21, 2026: ACRV's Quality Score is -11 (Poor), #268 of 273 in Biotech. Insiders sold $46K in the last 6 months (Form 4).

What does ACRV's Quality Score say?

ACRV scores -11 today, which Breakaway calls Poor. It is #268 of 273 in Biotech by Quality Score, with 1 of 14 chart checks firing. Down 49% in a year while the S&P 500 rose 7%. Cash lasts about 4 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is ACRV's Quality Score?

ACRV scores -11 today, which Breakaway calls Poor (below zero). That is #268 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ACRV's -11.

Are insiders buying ACRV?

6 insiders sold $46K across 17 filings in the last 6 months. No open-⁠market buys on record. The newest is Peter Blume-⁠Jensen, President and CEO, who sold $2K on Nov 17. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,170 stocks rankedSee all 3,170 stocks rankedStart Pro

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

What's next for Acrivon Therapeutics: from its SEC filings and ClinicalTrials.gov, the company's words, the registry's dates, and arithmetic, not a forecast. Companies often miss the dates they set.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.